Sopan Pharmaceuticals Limited has officially opened its Initial Public Offering (IPO) today, Chaitra 9, specifically targeting Nepalese citizens employed abroad. This initial phase marks the beginning of the company’s capital mobilization, as it prepares to offload 25% of its issued capital.
IPO Breakdown and Allocation
The company received regulatory approval to issue 4,290,000 shares, valued at NPR 429 million. This represents a significant portion of its NPR 1.716 billion issued capital. The allocation strategy is divided as follows:
- Foreign Employment Category: 429,000 shares (10% of the offering) are reserved for Nepalese workers abroad who have obtained labor approval from the Government of Nepal.
- Collective Investment Funds: 214,500 shares (5%) have been set aside.
- Employee Reserves: 171,600 shares (4%) are dedicated to company staff.
- General Public: The remaining 3,474,900 shares will be made available to the general public in a subsequent phase.
Sopan Pharmaceuticals IPO Key Details:
| Feature | Details |
| Opening Date | Chaitra 9, 2082 (Today) |
| Closing Date (Early) | Chaitra 12, 2082 |
| Closing Date (Extended) | Chaitra 23, 2082 (if not fully subscribed) |
| Minimum Application | 10 Shares (NPR 1,000) |
| Maximum Application | 11,000 Shares (NPR 1.1 Million) |
| Issue Manager | NMB Capital Limited |
| Credit Rating | CareNP B (High Risk) |
Subscription Details and Timeline
Eligible investors can apply for a minimum of 10 shares and a maximum of 11,000 shares.
For Nepalese workers abroad, the subscription window is currently set to close on Chaitra 12. However, if the issue is not fully subscribed by the end of this period, the deadline will be extended to Chaitra 23.
ALSO: Share Market News Nepal: NEPSE Updates, IPOs & Stock Analysis
Application Process
NMB Capital Limited is serving as the issue and sales manager. Applications can be submitted through the C-ASBA system via the ‘Mero Share’ software. This service is accessible through all ASBA-member banks and financial institutions approved by the Nepal Securities Board (SEBON).
Financial Health and Risk Assessment
Prospective investors should note that Care Rating Nepal has assigned a ‘CareNP B’ issuer rating to the company. This rating suggests a high level of risk regarding the company’s ability to meet its financial obligations.
Regarding investment recovery, the company’s ordinary payback period is estimated at 8.11 years, while the discounted payback period stands at 11.35 years. Sopan Pharmaceuticals reported a Net Present Value (NPV) of NPR 15,975,939,257 and an Internal Rate of Return (IRR) of 23.63%.
How to Apply (For Nepalese Abroad)
If you are currently working overseas and have obtained the necessary labor approval, you can apply through the following steps:
- Mero Share Online: Log in to your Mero Share account provided by CDS and Clearing Limited.
- C-ASBA System: Navigate to the “My ASBA” section.
- Bank Approval: Select the Sopan Pharmaceuticals IPO from the current issues. Ensure your bank account (linked with CRN) has sufficient funds for the number of shares you are applying for.
- Submission: Confirm your application. Your bank will block the amount until the allotment process is completed.
